| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.8 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.017 | 0.8 |